After a successful entry into the biosimilars market over the past 18 months, Amneal wants to continue its ride on the “next wave of affordable medicines” and is on the lookout for two or three biosimilar in-licensing opportunities in 2024.
“Given the market growth and importance of biosimilars, this is a key area of strategic focus and investment for Amneal
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?